AUT-00201 is under clinical development by Autifony Therapeutics and currently in Phase I for Myoclonic Seizure. According to GlobalData, Phase I drugs for Myoclonic Seizure have a 100% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AUT-00201’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AUT-00201 overview

AUT-00201 is under development for the treatment of progressive myoclonic epilepsy and ataxia. The drug is administered through oral route. It is a small molecule and acts by targeting Kv3.1 and 3.2 ion channel. It was also under development for schizophrenia and hearing disorders.

Autifony Therapeutics overview

Autifony Therapeutics, is a biotechnology company aims to develop new drugs to treat serious disorders of the central nervous system. The company’s pipeline products includes clinical stage programmes for Schizophrenia, Fragile X and earlier stage programmes focused on ALS, age related hearing loss, and Alzheimer’s disease. Autifony Therapeutics is headquartered in Stevenage, Hertfordshire, the UK.

For a complete picture of AUT-00201’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.